Daily Cardiology Research Analysis
Three high-impact cardiology studies advance mechanisms and precision interventions: stellate ganglion satellite glial cells drive post–myocardial infarction sympathetic hyperexcitability and arrhythmogenesis via P2Y1R/IGFBP2 signaling; reduced PAI-1 protects against cardiovascular aging phenotypes with pharmacologic reversibility; and a two-step high-throughput platform identifies genotype-specific rescue of Kv11.1 (hERG) trafficking in long QT syndrome using a repurposed drug (evacetrapib).
Summary
Three high-impact cardiology studies advance mechanisms and precision interventions: stellate ganglion satellite glial cells drive post–myocardial infarction sympathetic hyperexcitability and arrhythmogenesis via P2Y1R/IGFBP2 signaling; reduced PAI-1 protects against cardiovascular aging phenotypes with pharmacologic reversibility; and a two-step high-throughput platform identifies genotype-specific rescue of Kv11.1 (hERG) trafficking in long QT syndrome using a repurposed drug (evacetrapib).
Research Themes
- Neurocardiac modulation post-myocardial infarction
- Vascular aging and serpin biology (PAI-1) as therapeutic targets
- Genotype-specific drug discovery for ion channelopathies
Selected Articles
1. Inhibition of Satellite Glial Cell Activation in Stellate Ganglia Prevents Ventricular Arrhythmogenesis and Remodeling After Myocardial Infarction.
Chemogenetic manipulation of stellate ganglion satellite glial cells showed that their activation drives early sympathetic hyperexcitability and ventricular electrophysiological instability after MI, whereas inhibition stabilizes electrophysiology and attenuates neural and structural remodeling. Bulk RNA-seq and pharmacologic blockade implicated P2Y1R/IGFBP2 signaling as a key pathway linking SGCs to sympathetic neurons.
Impact: Reveals a glia-mediated mechanism of post-MI arrhythmogenesis and identifies a druggable P2Y1R/IGFBP2 pathway, opening a new neuromodulatory strategy beyond traditional cardiomyocyte targets.
Clinical Implications: Suggests that targeting stellate ganglion glial signaling (e.g., P2Y1R inhibition) could complement existing post-MI therapies to reduce ventricular arrhythmias and adverse remodeling, and refines the rationale for sympathetic neuromodulation approaches.
Key Findings
- Stellate ganglion SGC activation correlated with norepinephrine release and induced ventricular electrophysiological instability within 2 hours post-MI.
- Inhibition of SGCs suppressed MI-induced sympathetic hyperexcitability and improved ventricular remodeling and function by day 7.
- P2Y1R/IGFBP2 signaling mediated SGC–sympathetic neuron crosstalk; blocking P2Y1R attenuated the pro-arrhythmic effects.
Methodological Strengths
- Bidirectional, cell-specific chemogenetic manipulation in vivo with multimodal phenotyping (neural, electrophysiological, structural).
- Mechanistic validation via bulk RNA sequencing and pharmacologic pathway blockade (P2Y1R).
Limitations
- Preclinical rat models; absence of human interventional validation.
- Short-term observation windows (early hours to 7 days) may not capture chronic remodeling dynamics.
Future Directions: Translate P2Y1R/IGFBP2-targeted neuromodulation to large-animal models and early-phase human studies; evaluate synergy with existing post-MI therapies and device-based sympathetic modulation.
BACKGROUND: Hyperactivity of sympathetic neurons in the stellate ganglia (SG) contributes to ventricular arrhythmias and remodeling postmyocardial infarction (MI). However, the role of satellite glial cells (SGCs) surrounding the neurons in this process remains unknown. METHODS: SGC-specific chemogenetic manipulation was locally applied to modulate SG-SGC activity dual-directionally in the rats with naïve or infarcted hearts. Subsequently, cardiac sympathetic neural activity and ventricular electrophysiological stability in response to stimulation were evaluated, as well as cardiac neural and structural remodeling post-MI. SG bulk RNA sequencing and the interaction between SGCs and sympathetic neurons isolated from SG were used to explore the underpinning mechanisms. RESULTS: SG-SGC excitation increased SG neural activity and ventricular electrophysiological instability in rats with naïve hearts, whereas its inhibition influenced none of the above under physiological conditions. Of note, 2-hour-MI provoked SG-SGC activation that positively correlated with cardiac sympathetic neurotransmitter (norepinephrine) release. Accordingly, SGC activation in the SG enhanced cardiac sympathetic hyperactivity 2 hours post-MI, whereas SG-SGC inhibition suppressed MI-induced cardiac sympathetic hyperexcitability. Moreover, the persistent inhibition of SG-SGCs improved ventricular remodeling and dysfunction, alleviated SG and ventricular sympathetic nerve sprouting 7 days post-MI. In addition, the bulk RNA sequencing with SG and pharmacological purinergic P2Y1R (P2Y1 receptor) blockage indicated that P2Y1R/IGFBP2 (insulin-like growth factor-binding protein 2) signaling mediated the effects of SG-SGC activation on cardiac sympathetic hyperexcitability post-MI, and IGFBP2 bridged the interaction between the neurons and surrounding SGCs. CONCLUSIONS: SGC inhibition in SG rectifies cardiac sympathetic hyperactivity, stabilizes ventricular electrophysiological properties, and alleviates cardiac structural and neural remodeling post-MI, thereby preventing ventricular arrhythmias and cardiac dysfunction. Neuromodulation targeting SG-SGCs exhibits a safe and fruitful strategy for the treatment of MI.
2. Plasminogen activator inhibitor 1 promotes aortic aging-like pathophysiology in humans and mice.
A humanized PAI-1 loss-of-function mouse model exhibited 17% lifespan extension and resistance to vascular aging phenotypes under l-NAME stress, with scRNA-seq implicating ECM regulator downregulation and smooth muscle cell plasticity. Pharmacological PAI-1 inhibition normalized blood pressure and reversed increased arterial stiffness, positioning PAI-1 as a causal driver and therapeutic target in cardiovascular aging.
Impact: Establishes causal links between PAI-1 levels and cardiovascular aging with both genetic and pharmacologic interventions and provides single-cell mechanistic insight into ECM remodeling.
Clinical Implications: Supports therapeutic development of PAI-1 inhibitors for age-related vascular stiffness, hypertension, and diastolic dysfunction; informs biomarker strategies around PAI-1/SERPINE1 for risk stratification.
Key Findings
- Serpine1TA700/+ mice showed 17% increased lifespan and reduced PWV/SBP with preserved LV diastolic function under l-NAME stress.
- PAI-1 overexpression accelerated cardiovascular aging metrics, contrasting with protection in the loss-of-function model.
- scRNA-seq revealed downregulation of ECM regulators (Ccn1, Itgb1) and enrichment of plastic smooth muscle cell clusters; pharmacologic PAI-1 inhibition normalized SBP and reversed PWV elevation.
Methodological Strengths
- Humanized genetic model combined with pharmacologic inhibition for bidirectional causal inference.
- Single-cell transcriptomics providing cell-state–level mechanistic insights into ECM remodeling.
Limitations
- Predominantly murine data; human interventional validation absent.
- Vascular stress induced by l-NAME may not capture the full spectrum of human aging stimuli.
Future Directions: Assess PAI-1 inhibition in large-animal models and early human trials targeting arterial stiffness and diastolic dysfunction; explore combination strategies with antihypertensives and antifibrotics.
Plasminogen activator inhibitor 1 (PAI-1), encoded by SERPINE1, contributes to age-related cardiovascular disease (CVD) and other aging-related pathologies. Humans with a heterozygous loss-of-function SERPINE1 variant exhibit protection against aging and cardiometabolic dysfunction. We engineered a mouse model mimicking the human mutation (Serpine1TA700/+) and compared cardiovascular responses with WT littermates. Serpine1TA700/+ mice lived 17% longer than did littermate control mice. Under l-NG-nitro-arginine methyl ester-induced (l-NAME-induced) vascular stress, Serpine1TA700/+ mice exhibited diminished pulse wave velocity (PWV), lower systolic blood pressure (SBP), and preserved left ventricular diastolic function compared with controls. Conversely, PAI-1-overexpressing mice had measurements indicating accelerated cardiovascular aging. Single-cell transcriptomics of Serpine1TA700/+ aortas revealed a vascular-protective mechanism with downregulation of the extracellular matrix regulators Ccn1 and Itgb1. Serpine1TA700/+ aortas were also enriched in a cluster of smooth muscle cells that exhibited plasticity. Finally, PAI-1 pharmacological inhibition normalized SBP and reversed l-NAME-induced PWV elevation. These findings demonstrate that PAI-1 reduction protects against cardiovascular aging-related phenotypes, while PAI-1 excess promotes vascular pathological changes. Taken together, PAI-1 inhibition represents a promising strategy to mitigate age-related CVD.
3. High-throughput screens identify genotype-specific therapeutics for channelopathies.
A two-step platform screened 1,680 approved medicines with a thallium-flux trafficking assay across Kv11.1 (hERG) LQTS variants, identifying evacetrapib as a trafficking and activation corrector. Deep mutational scanning mapped the spectrum of responsive missense variants, enabling mutation-specific repurposing strategies for personalized therapy in channelopathies.
Impact: Provides a generalizable framework that couples phenotypic drug screening with deep mutational maps to deliver genotype-specific therapies, exemplified in LQTS.
Clinical Implications: Enables precision selection of patients with specific hERG variants likely to benefit from evacetrapib-like trafficking correctors, informing trial design and personalized therapy for LQTS.
Key Findings
- High-throughput screen of 1,680 medicines identified evacetrapib as a candidate that improves membrane trafficking and activates Kv11.1 channels.
- Deep mutational scanning prospectively mapped missense variants in a hotspot region responsive to evacetrapib treatment.
- Demonstrates a scalable paradigm for mutation-specific drug repurposing in rare ion channel disorders.
Methodological Strengths
- Integration of phenotypic high-throughput screening with deep mutational scanning for prospective variant stratification.
- Use of a functional trafficking assay directly linked to the pathophysiology of LQTS.
Limitations
- Preclinical in vitro assays without in vivo efficacy or safety data, and evacetrapib’s prior CETP-related safety profile may complicate translation.
- Focused on hotspot variants; generalizability to all pathogenic regions needs further validation.
Future Directions: Conduct variant-enriched clinical studies to test efficacy/safety in responsive LQTS genotypes; extend the platform to other ion channelopathies and integrate with patient-derived models.
Genetic diseases such as ion channelopathies substantially burden human health. Existing treatments are limited and not genotype specific. Here, we report a 2-step high-throughput approach to rapidly identify drug candidates for repurposing as genotype-specific therapy. We first screened 1,680 medicines using a thallium-flux trafficking assay against Kv11.1 gene variants causing long QT syndrome (LQTS), an ion channelopathy associated with fatal cardiac arrhythmia. We identified evacetrapib as a suitable drug candidate that improves membrane trafficking and activates channels. We then used deep mutational scanning to prospectively identify all Kv11.1 missense variants in an LQTS hotspot region responsive to treatment with evacetrapib. Combining high-throughput drug screens with deep mutational scanning establishes a paradigm for mutation-specific drug discovery translatable to personalized treatment of carriers with rare genetic disorders.